Field Medical – a pioneer in cardiac pulsed field ablation (PFA) technology – announced the closing of $40 million in Series A funding round. This funding round includes $20 million in new capital and the conversion of $20 million in seed-round debt. The participants include several leading strategics, venture capital firms, and family offices, with multiple seed investors reinvesting, emphasizing strong confidence in the company’s initial focus on ventricular tachycardia (VT) and the broader versatility of its technology.
What Field Medical does: Field Medical is developing transformative technology for treating all cardiac arrhythmias, including VT and AF. And the FieldForce Ablation System, featuring the first built-for-purpose, contact force focal PFA catheter, enables an instantaneous ablation workflow, with therapy delivered in a fraction of a second.
Some recent results from the VCAS (VT) and PULSE (AF) pilot studies demonstrate the system’s versatility. Powered by FieldBending, the company’s proprietary technology that offers brief and high-intensity electric fields, the System is positioned as the single, advanced solution for treating a full spectrum of cardiac arrhythmias.
What the funding will be used for: The funding will support the completion of two pilot studies – VCAS for VT and Field PULSE for atrial fibrillation (AF) – as well as continued development of Field’s commercial PFA system and operational scale-up in preparation for VERITAS, the company’s pivotal trial focused on VT.
KEY QUOTES:
“This financing is a pivotal milestone as we advance in redefining how electrophysiologists approach ablation therapy. With the support of our investors, we are accelerating the development of the FieldForce™ Ablation System, building on early clinical evidence, and moving closer to our commercial goal of expanding access to next-generation PFA solutions for cardiac ablation.”
- Steven Mickelsen, M.D., founder and chief executive officer of Field Medical
“We are encouraged by the strong support and confidence from both new investors and our reinvesting seed-round investor base. This funding enables us to execute our strategic plan with speed and focus as we transition from early-stage innovation into commercial readiness.”
• ⁃ Oskar Dadason, chief financial officer
